Carl Zeiss Meditec Stock Current Valuation
| CZMWF Stock | USD 61.22 0.00 0.00% |
Valuation analysis of Carl Zeiss Meditec helps investors to measure Carl Zeiss' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Carl Zeiss' price fluctuation is very steady at this time. Calculation of the real value of Carl Zeiss Meditec is based on 3 months time horizon. Increasing Carl Zeiss' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Carl pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Carl Zeiss Meditec. Since Carl Zeiss is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Carl Pink Sheet. However, Carl Zeiss' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 61.22 | Real 55.13 | Hype 61.22 | Naive 56.8 |
The real value of Carl Pink Sheet, also known as its intrinsic value, is the underlying worth of Carl Zeiss Meditec Company, which is reflected in its stock price. It is based on Carl Zeiss' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Carl Zeiss' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Carl Zeiss Meditec helps investors to forecast how Carl pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Carl Zeiss more accurately as focusing exclusively on Carl Zeiss' fundamentals will not take into account other important factors: Carl Zeiss Meditec Company Current Valuation Analysis
Carl Zeiss' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Carl Zeiss Current Valuation | 12.07 B |
Most of Carl Zeiss' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Carl Zeiss Meditec is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Carl Zeiss Meditec has a Current Valuation of 12.07 B. This is 15.99% lower than that of the Healthcare sector and 31.97% higher than that of the Medical Instruments & Supplies industry. The current valuation for all United States stocks is 27.42% higher than that of the company.
Carl Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Carl Zeiss' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Carl Zeiss could also be used in its relative valuation, which is a method of valuing Carl Zeiss by comparing valuation metrics of similar companies.Carl Zeiss is currently under evaluation in current valuation category among its peers.
Carl Fundamentals
| Return On Equity | 0.16 | |||
| Return On Asset | 0.0955 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.21 % | |||
| Current Valuation | 12.07 B | |||
| Shares Outstanding | 89.44 M | |||
| Shares Owned By Insiders | 59.10 % | |||
| Shares Owned By Institutions | 22.23 % | |||
| Price To Earning | 75.63 X | |||
| Price To Book | 6.17 X | |||
| Price To Sales | 6.34 X | |||
| Revenue | 1.9 B | |||
| Gross Profit | 1.13 B | |||
| EBITDA | 419.49 M | |||
| Net Income | 293.91 M | |||
| Cash And Equivalents | 8.4 M | |||
| Cash Per Share | 0.09 X | |||
| Total Debt | 120.05 M | |||
| Debt To Equity | 0.07 % | |||
| Current Ratio | 3.35 X | |||
| Book Value Per Share | 22.53 X | |||
| Cash Flow From Operations | 188.2 M | |||
| Earnings Per Share | 2.93 X | |||
| Price To Earnings To Growth | 3.93 X | |||
| Target Price | 138.8 | |||
| Number Of Employees | 4.22 K | |||
| Beta | 0.8 | |||
| Market Capitalization | 12.53 B | |||
| Total Asset | 2.4 B | |||
| Retained Earnings | 458 M | |||
| Working Capital | 573 M | |||
| Current Asset | 859 M | |||
| Current Liabilities | 286 M | |||
| Z Score | 62.4 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 2.4 B | |||
| Last Dividend Paid | 1.1 |
About Carl Zeiss Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Carl Zeiss Meditec's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Carl Zeiss using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Carl Zeiss Meditec based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Carl Pink Sheet
Carl Zeiss financial ratios help investors to determine whether Carl Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Carl with respect to the benefits of owning Carl Zeiss security.